Vistagen reports Q3 FY2025 net loss $14.1M; fasedienol Phase 3 progressing

Vistagen Therapeutics, Inc.

2025-Q3 EPS reported -$1.23 vs consensus -$0.49 ▼ miss (-153.3%)

Net loss $14.1M for Q3 ended Dec 31, 2024, vs $6.4M YoY; R&D expense rose to $11.3M from $4.5M.
Cash and marketable securities $88.6M as of Dec 31, 2024.
Fasedienol PALISADE-3 and PALISADE-4 Phase 3 trials for SAD ongoing; top-line results expected later 2025.
Positive exploratory Phase 2A results for PH284 in cancer cachexia announced.
IND-enabling program for PH80 for menopausal hot flashes continuing; Phase 2B planning for itruvone in MDD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.